NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 11,538,462 shares of its common…
NEW YORK, Nov. 18, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced the pricing of its previously announced underwritten public offering of 11,538,462 shares of its common stock at a public offering price of $13.00 per share. All of the shares in the offering will be sold by SELLAS, with gross proceeds to SELLAS expected to be $150.0 million before deducting underwriting discounts and commissions and offering expenses. In addition, SELLAS has also granted the underwriters a 30-day option to purchase up to 1,730,769 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on November 20, 2026, subject to the satisfaction of customary closing conditions.
De nouveaux tableaux de bord et une vérification des documents validée par des experts offrent aux acheteurs une visibilité accrue sur les performances des fournisseurs, la conformité et la traçabilité jusqu’à l’origine De nouveaux tableaux de bord et une vérification des documents validée par des experts offrent aux acheteurs une visibilité accrue sur les performances… ...
Success Knocks Recognition Highlights CallTower's Global Growth and Leadership Across UCaaS, CCaaS, Customer Experience, and AI-Powered Communications Success Knocks Recognition Highlights CallTower's Global Growth and Leadership Across UCaaS, CCaaS, Customer Experience, and AI-Powered Communications ...